These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 29985084)

  • 1. Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
    Oshima Y; Tanimoto T; Yuji K; Tojo A
    Mult Scler; 2019 Jul; 25(8):1141-1149. PubMed ID: 29985084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atypical Multiple Sclerosis Lesions or Progressive Multifocal Leukoencephalopathy Lesions: That Is the Question.
    De Mercanti SF; Gned D; Matta M; Iudicello M; Franchin E; Clerico M
    J Investig Med High Impact Case Rep; 2020; 8():2324709620939802. PubMed ID: 32646245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Progressive Multifocal Leukoencephalopathy: An Overview of Current Topics].
    Yukitake M
    Brain Nerve; 2022 Oct; 74(10):1179-1187. PubMed ID: 36198643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients.
    Alping P; Askling J; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Langer-Gould A; Lycke J; Nilsson P; Salzer J; Svenningsson A; Vrethem M; Olsson T; Piehl F; Frisell T
    Ann Neurol; 2020 May; 87(5):688-699. PubMed ID: 32056253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and effectiveness of disease-modifying therapies after switching from natalizumab.
    Zeineddine M; Al-Roughani R; Farouk Ahmed S; Khoury S; El-Ayoubi N; Al-Mahdawi A; Al-Khabouri J; Al-Asmi A; Chentouf A; Inshasi J; Gouider R; Mrabet S; Shalaby N; Massouh J; Mohamed Ramzy Hasan Mohamed F; Al-Hajje A; Salameh P; Dimassi H; Boumediene F; Yamout B
    Mult Scler; 2024 Jul; 30(8):1026-1035. PubMed ID: 39054846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.
    Ho PR; Koendgen H; Campbell N; Haddock B; Richman S; Chang I
    Lancet Neurol; 2017 Nov; 16(11):925-933. PubMed ID: 28969984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PML: The Dark Side of Immunotherapy in Multiple Sclerosis.
    Warnke C; Olsson T; Hartung HP
    Trends Pharmacol Sci; 2015 Dec; 36(12):799-801. PubMed ID: 26497099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TSPO PET imaging of natalizumab-associated progressive multifocal leukoencephalopathy.
    Mahler C; Schumacher AM; Unterrainer M; Kaiser L; Höllbacher T; Lindner S; Havla J; Ertl-Wagner B; Patzig M; Seelos K; Neitzel J; Mäurer M; Krumbholz M; Metz I; Brück W; Stadelmann C; Merkler D; Gass A; Milenkovic V; Bartenstein P; Albert NL; Kümpfel T; Kerschensteiner M
    Brain; 2021 Oct; 144(9):2683-2695. PubMed ID: 33757118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-induced progressive multifocal leukoencephalopathy: Lessons learned from contrasting natalizumab and rituximab.
    Vermeer NS; Straus SM; Mantel-Teeuwisse AK; Hidalgo-Simon A; Egberts AC; Leufkens HG; De Bruin ML
    Clin Pharmacol Ther; 2015 Nov; 98(5):542-50. PubMed ID: 26347128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations.
    van Kempen ZL; Leurs CE; Vennegoor A; Wattjes MP; Rispens T; Uitdehaag BM; Killestein J
    Mult Scler; 2017 Jun; 23(7):995-999. PubMed ID: 28112019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dealing with highly active multiple sclerosis after natalizumab-associated PML: could rituximab be of help?
    Mancinelli CR; Scarpazza C; Santuccio G; De Rossi N; Capra R
    Neurol Sci; 2018 May; 39(5):965-966. PubMed ID: 29302813
    [No Abstract]   [Full Text] [Related]  

  • 12. Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy.
    Hoepner R; Kolb EM; Dahlhaus S; Hellwig K; Adams O; Kleiter I; Salmen A; Schneider R; Lukas C; Chan A; Berger JR; Gold R
    Mult Scler; 2017 May; 23(6):830-835. PubMed ID: 27600113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on monitoring and adverse effects of approved second-generation disease-modifying therapies in relapsing forms of multiple sclerosis.
    Dubey D; Cano CA; Stüve O
    Curr Opin Neurol; 2016 Jun; 29(3):278-85. PubMed ID: 27027553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Classifying PML risk with disease modifying therapies.
    Berger JR
    Mult Scler Relat Disord; 2017 Feb; 12():59-63. PubMed ID: 28283109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Presentation and Outcome in S1P-RM and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy: A Multicenter Cohort Study.
    Blant JC; De Rossi NN; Gold R; Maurousset A; Kraemer M; Romero-Pinel L; Misu T; Ouallet JC; Pallix Guyot M; Gerevini S; Bakirtzis C; Piñar Morales R; Vlad B; Karypidis P; Moisset X; Derfuss TJ; Jelcic I; Martin-Blondel G; Ayzenberg I; McGraw C; Laplaud DA; Du Pasquier RA; Bernard-Valnet R;
    Neurol Neuroimmunol Neuroinflamm; 2024 Sep; 11(5):e200281. PubMed ID: 38991170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs.
    D'Amico E; Zanghì A; Leone C; Tumani H; Patti F
    Drug Saf; 2016 Dec; 39(12):1163-1174. PubMed ID: 27696299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
    Faulkner M
    Expert Opin Drug Saf; 2015; 14(11):1737-48. PubMed ID: 26394704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful pregnancy after natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis.
    Pitarokoili K; Hellwig K; Lukas C; Gold R
    Mult Scler; 2017 Mar; 23(3):483-486. PubMed ID: 28260421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing understanding of individual risk and symptoms of progressive multifocal leukoencephalopathy in patients prescribed natalizumab for multiple sclerosis.
    Rath L; Vijiaratnam N; Skibina O
    Intern Med J; 2017 Feb; 47(2):194-199. PubMed ID: 27862809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned.
    Major EO; Yousry TA; Clifford DB
    Lancet Neurol; 2018 May; 17(5):467-480. PubMed ID: 29656742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.